Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1628 1692
This examiner grants 34% of resolved cases
Rayna B. Rodriguez, in Tech Center 1600 and Art Unit 1628, has 587 resolved cases. The allowance rate is 33.6 percent, and the median days to allowance is 1264. These metrics indicate a rigorous examination process with a low probability of success and a wait of over three years. This is a challenging environment for applicants in the biotechnology and organic chemistry sectors and requires a patient approach.
The interview lift is 19.2 percent, suggesting that an interview can help improve the 33.6 percent base rate. Practitioners should expect a long 1264-day median timeline and should use interviews as a tactic to overcome the examiner's objections. For the 587 resolved cases, the data shows that direct communication is a tool for navigating the complexities of Art Unit 1628. While the baseline success rate is 33.6 percent, the lift from interviews provides a path to improving the odds of a grant. In Tech Center 1600, a strategy that combines written arguments with proactive verbal advocacy is useful for success under this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17845275 | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA | Final Rejection | Deciphera Pharmaceuticals, LLC |
| 18785844 | CDK INHIBITORS | Non-Final OA | Genentech, Inc. |
| 18544236 | METHODS OF TREATING CANCER USING B-RAF INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS | Final Rejection | Genentech, Inc. |
| 18685717 | NOVEL PYRAZINYL-TRIAZOLE COMPOUNDS AS PESTICIDES | Non-Final OA | Bayer Aktiengesellschaft |
| 18622241 | Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin | Non-Final OA | Board of Regents of the University of Nebraska |
| 18009682 | CYCLOPROPYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS | Final Rejection | AMGEN INC. |
| 18026515 | METHODS OF TREATING RIBONUCLEOTIDE REDUCTASE-RELATED DISEASES WITH A RIBONUCLEOTIDE REDUCTASE INHIBITOR | Final Rejection | TAIHO PHARMACEUTICAL CO., LTD. |
| 18429778 | Combination Therapy For Prostate Cancer | Non-Final OA | Janssen Pharmaceutica NV |
| 17916504 | NOVEL FORMUATIONS | Final Rejection | ARECOR LIMITED |
| 18850348 | TREATMENT OF ANXIETY | Non-Final OA | GH RESEARCH IRELAND LIMITED |
| 18444342 | Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | Non-Final OA | Corcept Therapeutics Incorporated |
| 17255963 | NEW MOLECULAR TWEEZERS AGAINST NEUROLOGICAL DISORDERS AND VIRAL INFECTIONS | Final Rejection | UNIVERSITÄT ULM |
| 16078706 | COMBINATION THERAPIES COMPRISING IMMUNO-ONCOLOGY AGENTS AND BELINOSTAT | Final Rejection | ONXEO |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy